Amgen suffers setback as patent office refuses to review competitor’s drug
The U.S. Patent and Trademark Office handed Amgen a potential setback Jan. 14 when it declined to review two patent expiration dates on a competitor’s drug. In June, Thousand Oaks-based biotech giant Amgen asked the agency to review two formulation patents for Humira, made by Chicago-based competitor AbbVie, arguing that the patents should not have Read More →
Read More →
Tri-Counties has new appeal for biotech startups
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Settlement ends Amgen drug kickback saga
A drug kickback program is finally behind Amgen, the Thousand Oaks-based pharmaceutical giant. Louisville, K.Y.-based PharMerica was the last of three companies to settle lawsuits relating to Amgen allegedly paying kickbacks to PharMerica and another company to prescribe patients the anemia drug Aranesp. PharMerica settled the suit for $2.5 million in December, Louisville Business First Read More →
Read More →Voters to decide Ventura County growth
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Thousand Oaks’ Sports Academy aims to develop student athletes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Thousand Oaks Boulevard improvements working
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen seeks European OK of biosimilar drug, partners with Merck on studies
Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
